Akèy › Maladi otoim › North Carolina › Durham
Etid klinik pou Maladi otoim nan Durham, NC
15 etid pou Maladi otoim ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Environmental Risk Factors for the Anti-synthetase Syndrome
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NIEHS Clinical Research Unit (CRU), Research Triangle Park · 7 mi lwen
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Duke University Hospital, Durham
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Ap rekriteFaz 2/3
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients, Durham
- University of North Carolina at Chapel Hill - Accepting Adult Patients, Chapel Hill · 10 mi lwen
Daratumumab in Primary Antiphospholipid Syndrome
Ap rekriteFaz 1/2
- Duke University, Durham
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Ap rekriteFaz 1
- Duke University Medical Center, Durham
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Duke University Hospital, Durham
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Ap rekriteFaz 3
- GSK Investigational Site, Durham
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Ap rekriteFaz 1/2
- UNC Chapel Hill, Chapel Hill · 10 mi lwen
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Ap rekriteFaz 2/3
- Duke University, Durham
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Ap rekriteFaz 3
- Duke University Medical Center, Durham
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Ap rekriteFaz 3
- Site Number - 1013, Durham
- Site Number - 1020, Chapel Hill · 10 mi lwen
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Ap rekriteFaz 1
- Duke University, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Ap rekriteFaz 1
- Duke University Health System, Durham
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Duke University, Durham
Etid Maladi otoim nan lòt vil
- Houston, TX21 etid
- Washington, DC19 etid
- New York City, NY19 etid
- Philadelphia, PA16 etid
- Boston, MA13 etid
- Los Angeles, CA12 etid
- Chicago, IL12 etid
- Dallas, TX9 etid
- Cleveland, OH8 etid
- Atlanta, GA8 etid
- Milwaukee, WI8 etid
- Portland, OR8 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè poumon32 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Lukemi lenfositè kwonik27 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.